Estradiol Serum Levels in Menopausal Women With and Without Vasomotor Syndrome in Medan


Vasomotor syndrome is the most commonly complained syndrome in menopause women. The main mechanism is the decrease in estrogen which causes increasing of body's core temperature and overactivity of the parasympathetic nervous system. Estradiol is the most abdudant and most potent estrogen derivate that works in major receptors throughout the body. This study aimed to determine difference of estradiol serum levels between women with and without vasomotor syndromes and among the symptoms severity. This study was conducted in 50 menopausal women in the Department of Obstetrics and Gynecology H. Adam Malik Hospital, Medan, Indonesia. Vasomotor symptoms was assessed by interview using three options of answers. Estradiol serum was analyezed using chemiluminescent principle in Prodia Laboratory. Data were tabulated and analyzed by SPSS. This study showed significant difference of mean estradiol serum levels between women with and without vasomotor syndromes (17.5 and 47.5 pg/ml, respectively; p=0.0001). Women with mild vasomotor syndromes had higher estradiol serum levels (23.9-29 pg/ml) than those with moderate (12-19.7 pg/ml) and severe (11.8 pg/ml) degree of syndromes. By using estradiol level as a marker, the presence vasomotor symptoms even its severeity should have been predicted earlier. Therefore, women can prepare to overcome those debilitating symptoms. Further and larger reseach is needed to make this study applicable in all clinical settings.

[1] B. Affandi, Masalah kesehatan pada menopause. Panduan menopause, Balai Penerbit FK UI, p. 57, (2000).

[2] L. Marosa, F. G. Siregar, and I. G. Munthe, Perbandingan Kadar Saliva 17ß Estradiol Pada Wanita Menopause Dengan Keluhan Dan Tanpa Keluhan Di, in RSUP H Adam Malik Dan RS Jejaring FK USU Medan, Fakultas Kedokteran USU, p. 78, IG Munthe, Medan, 2014.

[3] FG. Siregar, Perimenopausal and Postmenopausal Complaints in Paramedics Asseds by Menopause rating, IQSR-JDMS, 13–12, (2014).

[4] MS. Darmasetiawan, Seputar Masalah Wanita Menopause di Indonesia. Departemen Obstetri dan Ginekologi RSPAD Gatot Subroto, Departemen Obstetri dan Ginekologi RSPAD Gatot Subroto, p. 12, (2006).

[5] NA. Klein, MR Soules. Endocrine changes of the menopause, Clin Obstet Gynecol, 41, 912–20, (2004).

[6] G. A. Greendale, N. P. Lee, and E. R. Arriola, The menopause, Lancet, 353, no. 9152, 571–580, (1999).

[7] C. B. Hammond, Menopause and hormone replacement therapy: An overview, Obstetrics and Gynecology, 87, no. 2, (1996).

[8] N. Pramono, Upaya Meningkatkan Kualitas Hidup Manusia, Disampaikan pada Pidato Guru Besar Bagian Obstetri dan Ginekologi FK Undip, p. 18, (1998).

[9] R. B. Jappe, The Menopause and Perimenopausal Period, in Reproductive Endocrinology, 389–404, W.B. Sounders Company, Philadelphia, 3rd edition, 2005.

[10] L. Speroff, RH. Glass, and N. G. Kase, Neuroendocrinology, Clinical Gynecologic Endocrinology and Infertility, 5, Wilkins, Baltimore: William, 5th edition, 2010.

[11] M. Birkhauser, Life after The Menopause: A Demographic, Medical and Social Challenge, Medicographia, 21, p. 262, (2010).

[12] B. Affandi, Masalah Kesehatan Pada Menopause, Dalam, Baziad A, Affani B.(ed), in Panduan Menopause dan Terapi Hormon Pengganti, Edisi Pertama, 11–20, Jakarta, POGI-PERMI, 2004.

[13] A. Baziad, S. Lazuardi, and S. Darmawan, Seputar Masalah Menopause, in Dalam KSERI, 11–23, Proseding, Jakarta, 2002.

[14] J. Widya, Analisis Karakteristik Wanita Premenopause dalam Kesiapan Menghadapi Sindrom Menopause Di Kelurahan Pendrikan Lor Kecamatan Semarang Tengah Tahun 2011, Universitas Diponogoro, 1–35, (2011).

[15] M. I. Pernoll, The Non Reproductive Years, in Handbook of Obstetrics and Gynaecology, 743–54, McGraw Hill Inc, Philadelphia, 10th edition, 2001.

[16] IA. Rachman, Perubahan tubuh menjelang menopause dan gejala serta tanda yang menyertainya, Dalam, Menopause Masalah dan Penanggulangannya, FK UI, p. 19, (2006).

[17] N. Wahdi Pramono and S. T. Hidayat, Kadar Estradiol Serum Pada Wanita Menopause Dengan Dan Tanpa Sindroma Vasomotor, Fakultas Kedokteran Universitas Diponogoro, 1–38, (2003).

[18] T. Z. Jacob and A. Baziad, Endokrinologi Reproduksi. Edisi ke-1, KSERI, Jakarta, 2000.

[19] W. W. Hurt, Menopause, Novak’s Gynecology, 29, William and Wilkins, Baltimore, 12th edition, 2008.

[20] L. Speroff, R. H. Glass, and N. G. Kase, Menopause and Postmenopausal Hormon Therapy, in Clnical Gynecologic Endocrinology and Infertility, 5, 583–650, Wilkins, Baltimore: William, 5th edition, 2006.

[21] E. K. Smith and H. L. Judd, Menopause and Postmenopause, in Current Obstetric and Gynecologic Diagnosis and Treatment, 57, 1030–1049, Prentice-Heinemann, Philadelphia, 8th edition, 2007.

[22] G. A. Bachman, Vasomotor Flushes in Menopausal Women, Am J Obstet Gynaecol, 312–6, (2009).

[23] N. Dusitsin, Symptoms of The Menopause and Their Treatments, The Proceedings of the first Consensus Meeting on Menopause in the East Asian Region; Geneva: Medical Forum International, p. 37

[24] N. Panay, E. Versi, and M. Savvas, A comparison of 25 mg and 50 mg oestradiol implants in the control of climacteric symptoms following hysterectomy and bilateral salpingo-oophorectomy, British Journal of Obstetrics and Gynaecology, 107, no. 8, 1012–1016, (2000).

[25] H. G. Burger, The Menopause: Clinical Features and Associated Disoders, Medicographia, 21, 219–22, (2012).

[26] J. E. Blümel, P. Chedraui, G. Baron, E. Belzares, A. Bencosme, A. Calle, L. Danckers, M. T. Espinoza, D. Flores, G. Gomez, J. A. Hernandez-Bueno, H. Izaguirre, P. Leon-Leon,S. Lima, E. Mezones-Holguin, A. Monterrosa, D. Mostajo, D. Navarro, E. Ojeda, W. Onatra, M. Royer, E. Soto, K. Tserotas, and S. Vallejo, A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middleaged women, Menopause, 18, no. 7, 778–785, (2011).

[27] M. Kaczmarek, The timing of natural menopause in Poland and associated factors, Maturitas, 57, no. 2, 139–153, (2007).

[28] A. Kriplani and K. Banerjee, An overview of age of onset of menopause in northern India, Maturitas, 52, no. 3-4, 199–204, (2005).

[29] M. Pakarinen, J. Raitanen, R. Kaaja, and R. Luoto, Secular trend in the menopausal age in Finland 1997-2007 and correlation with socioeconomic, reproductive and lifestyle factors, Maturitas, 66, no. 4, 417–422, (2010).

[30] E. B. Gold, A. Colvin, N. Avis, J. Bromberger, G. A. Greendale, L. Powell, B. Sternfeld, and K. Matthews, Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of women’s health across the nation, American Journal of Public Health, 96, no. 7, 1226–1235, (2006).

[31] E. Amabebe, Relationship between Menopausal Sweating and Body Mass Index, Open Journal of Endocrine and Metabolic Diseases, 4, 137–146, (2007).

[32] M. Rizvanovic, D. Balic, Z. Begic, A. Babovic, G. Bogadanovic, and L. Kameric, Parity and menarche as risk factors of time of menopause occurrence., Medicinski arhiv, 67, no. 5, 336–338, (2013).

[33] J. L. Stanford, P. Hartge, L. A. Brinton, R. N. Hoover, and R. Brookmeyer, Factors influencing the age at natural menopause, Journal of Chronic Diseases, 40, no. 11, 995–1002, (1987).

[34] E. Y. Kwawukume, T. S. Ghosh, and J. B. Wilson, Menopausal age of Ghanaian women, International Journal of Gynecology and Obstetrics, 40, no. 2, 151–155, (1993).

[35] F. Olaolorun and T. Lawoyin, Age at menopause and factors associated with attainment of menopause in an urban community in Ibadan, Nigeria, Climacteric, 12, no. 4, 352–363, (2009).

[36] EK. Smith and H. L. Judd, Menopause and Postmenopause, DeCherney AH Pernoll LM Current Obstetric and Gynecologic Diagnosis and Treatment. Eigth Edition, 1030–49,vol. 57.